ArticleFrontiers in pharmacology2026
Salivary glands as the primary dose-limiting organ: an integrated dosimetry, efficacy, and toxicity study of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Targeted alpha therapy with Methods: In male nude mice bearing C4-2 xenografts, a dosimetry group (n = 32) received 5 kBq Results: The radiopharmaceutical demonstrated high purity and stability. Dosimetry revealed favorable pharmacokinetics, with the highest absorbed dose coefficient for the tumor (588 Gy/GBq). The mean absorbed dose to the parotid gland (0.56 Gy at 5 kBq) exceeded that to the kidneys (0.29 Gy). The TI_min was >1 for all animals. The 40 kBq dose induced significant tumor growth inhibition (TGI: 75.2%, P < 0.001) and delayed progression (P < 0.001). While renal function remained normal, histology revealed mild tubular injury. Salivary gland function, however, showed a profound and sustained decrease (>60%, P < 0.001). Strong correlations were found between tumor dose and TGI (ρ = 0.720), kidney dose and histology score (ρ = 0.643), and salivary gland dose and functional impairment (ρ = 0.776) (all P < 0.05). Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.